BRPI0011407B8 - molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão - Google Patents

molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão

Info

Publication number
BRPI0011407B8
BRPI0011407B8 BRPI0011407A BRPI0011407A BRPI0011407B8 BR PI0011407 B8 BRPI0011407 B8 BR PI0011407B8 BR PI0011407 A BRPI0011407 A BR PI0011407A BR PI0011407 A BRPI0011407 A BR PI0011407A BR PI0011407 B8 BRPI0011407 B8 BR PI0011407B8
Authority
BR
Brazil
Prior art keywords
fusion polypeptide
nucleic acid
producing
methods
acid molecule
Prior art date
Application number
BRPI0011407A
Other languages
English (en)
Portuguese (pt)
Inventor
D Yancopoulos George
J Papadopoulos Nicholas
Davis Samuel
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0011407(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BRPI0011407B1 publication Critical patent/BRPI0011407B1/pt
Publication of BRPI0011407B8 publication Critical patent/BRPI0011407B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
BRPI0011407A 1999-06-08 2000-05-23 molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão BRPI0011407B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08
PCT/US2000/014142 WO2000075319A1 (en) 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties

Publications (2)

Publication Number Publication Date
BRPI0011407B1 BRPI0011407B1 (pt) 2018-09-25
BRPI0011407B8 true BRPI0011407B8 (pt) 2021-05-25

Family

ID=22480568

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0011407A BRPI0011407B8 (pt) 1999-06-08 2000-05-23 molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
BR0011407-3A BR0011407A (pt) 1999-06-08 2000-05-23 Molécula de ácido nucléico isolada, polipeptìdeo de fusão, composição, vetor, sistema de vetor, sistema de vetor hospedeiro, métodos de produzir um polipeptìdeo de fusão.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0011407-3A BR0011407A (pt) 1999-06-08 2000-05-23 Molécula de ácido nucléico isolada, polipeptìdeo de fusão, composição, vetor, sistema de vetor, sistema de vetor hospedeiro, métodos de produzir um polipeptìdeo de fusão.

Country Status (32)

Country Link
EP (2) EP1183353B1 (enExample)
JP (2) JP4723140B2 (enExample)
KR (1) KR100659477B1 (enExample)
CN (3) CN100523187C (enExample)
AT (2) ATE293164T1 (enExample)
AU (2) AU779303B2 (enExample)
BE (1) BE2013C029I2 (enExample)
BR (2) BRPI0011407B8 (enExample)
CA (1) CA2376379C (enExample)
CY (2) CY1108883T1 (enExample)
CZ (2) CZ303656B6 (enExample)
DE (2) DE60041159D1 (enExample)
DK (2) DK1183353T3 (enExample)
ES (2) ES2319305T3 (enExample)
FR (1) FR13C0028I2 (enExample)
HR (1) HRP20010908B1 (enExample)
HU (3) HU229156B1 (enExample)
IL (3) IL146890A0 (enExample)
LT (1) LTC1183353I2 (enExample)
LU (1) LU92195I2 (enExample)
ME (2) MEP3208A (enExample)
MX (1) MXPA01012630A (enExample)
NO (4) NO330775B1 (enExample)
NZ (1) NZ515913A (enExample)
PL (1) PL208247B1 (enExample)
PT (2) PT1183353E (enExample)
RS (1) RS50073B (enExample)
RU (1) RU2265661C2 (enExample)
SK (1) SK287332B6 (enExample)
UA (1) UA74146C2 (enExample)
WO (1) WO2000075319A1 (enExample)
ZA (1) ZA200110068B (enExample)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
EP1575548B1 (en) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
ATE354592T1 (de) * 2003-03-28 2007-03-15 Regeneron Pharma Vegf-antagonisten zur behandlung von diabetes
AU2004247025B8 (en) * 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
US7429375B2 (en) 2003-05-16 2008-09-30 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for the treatment of CNS
MXPA05008973A (es) * 2003-05-28 2006-02-22 Regeneron Pharma Metodo de tratamiento de rechazo de trasplante de cornea.
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CA2519875C (en) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050112061A1 (en) * 2003-08-06 2005-05-26 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
ES2411504T3 (es) 2004-05-18 2013-07-05 Acorda Therapeutics, Inc. Métodos de purificación de condroitinasa y formulaciones estables de la misma
PL1767546T3 (pl) * 2004-06-08 2012-07-31 Chengdu Kanghong Biotechnologies Co Ltd Hamujące angiogenezę białka chimeryczne i ich zastosowanie
CA2567686A1 (en) * 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
CN1968709A (zh) * 2004-06-18 2007-05-23 瑞泽恩制药公司 用于治疗恶性胸腔积液的vegf抑制剂
AU2005267741A1 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
CN101094688B (zh) 2004-09-13 2013-05-01 建新公司 多聚构建体
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
WO2007038548A2 (en) 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
DK1962895T3 (da) † 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
EP2450442B1 (en) 2006-10-10 2017-07-19 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
MX359570B (es) 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
CN101838329A (zh) 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
HRP20180154T1 (hr) 2010-08-06 2018-03-09 Genzyme Corporation Pripravci vegf antagonista i njihova uporaba
EP2662385A4 (en) * 2011-01-07 2015-11-11 Chugai Pharmaceutical Co Ltd METHOD FOR IMPROVING THE PHYSICAL PROPERTIES OF ANTIBODIES
CN103533950A (zh) 2011-01-13 2014-01-22 瑞泽恩制药公司 Vegf拮抗剂在治疗血管生成眼病中的用途
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
JP6138815B2 (ja) 2011-12-01 2017-05-31 エーピー バイオサイエンシーズ， インコーポレイテッド 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
PL2846836T3 (pl) 2012-05-07 2020-01-31 Allergan, Inc. Sposób leczenia amd u pacjentów opornych na terapię anty- vegf
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
EP3628324A1 (en) 2013-11-05 2020-04-01 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
RU2702748C2 (ru) 2014-05-12 2019-10-11 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
WO2016008975A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
HUE057653T2 (hu) 2014-12-11 2022-05-28 Bayer Healthcare Llc Kis aktív choroidális neurovaszkularizáció lézióval jellemzett idõskori makuladegeneráció kezelése
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
RU2734958C2 (ru) 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
WO2017085253A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
AU2016356717B2 (en) 2015-11-18 2022-09-29 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
CN108697792A (zh) * 2015-11-19 2018-10-23 珠海泰瑞尚生物医药科技有限公司 用于结合vegf的方法和组合物
PT3384049T (pt) 2015-12-03 2023-08-18 Regeneron Pharma Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
WO2017129685A1 (en) 2016-01-26 2017-08-03 Formycon Ag Liquid formulation of a vegf antagonist
US20190300607A1 (en) 2016-10-12 2019-10-03 Daiichi Sankyo Company, Limited Composition containing anti-robo4 antibody and other agents
CA3043487A1 (en) 2016-11-21 2018-05-24 Just-Evotec Biologics Inc Aflibercept formulations and uses thereof
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
ES2887046T3 (es) 2017-08-17 2021-12-21 Just Evotec Biologics Inc Método de purificación de proteína glicosilada a partir de galectinas de las células hospedadoras y otros contaminantes
WO2019099965A1 (en) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
ES2946747T3 (es) 2017-11-27 2023-07-25 4D Molecular Therapeutics Inc Variantes de cápsides de virus adenoasociado y su utilización para inhibir la angiogénesis
AU2018375398C1 (en) 2017-11-30 2026-01-15 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11460452B2 (en) * 2017-12-13 2022-10-04 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
EP3730126B1 (en) 2017-12-22 2025-05-14 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
US11524053B2 (en) * 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
TW202016125A (zh) * 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
US20220204920A1 (en) 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
CA3150481A1 (en) 2019-09-03 2021-03-11 Amgen Inc. Injection device for drug delivery and packaging for the injection device
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2020393842A1 (en) 2019-11-25 2022-06-16 The Regents Of The University Of California Long-acting VEGF inhibitors for intraocular neovascularization
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
KR20220110555A (ko) 2019-12-06 2022-08-08 리제너론 파마슈티칼스 인코포레이티드 Vegf 미니-트랩 및 그의 사용 방법
CA3167020A1 (en) 2020-02-24 2021-09-02 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
WO2023092324A1 (zh) 2021-11-24 2023-06-01 苏州光度生物科技有限公司 多特异性配体结合分子及其应用
EP4549455A1 (en) * 2022-08-02 2025-05-07 Panolos Bioscience, Inc. Modified fusion protein and use thereof
TW202412840A (zh) 2022-09-16 2024-04-01 大陸商齊魯製藥有限公司 一種穩定的高濃度自緩衝藥物組合物
AU2024322540A1 (en) * 2023-08-04 2026-03-05 Panolos Bioscience, Inc. Conjugate of modified fusion protein and scfv, and use thereof
WO2025213011A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Method of assessing stopper movement in a drug delivery device

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
CA2376379A1 (en) 2000-12-14
YU86901A (sh) 2004-05-12
ES2319305T3 (es) 2009-05-06
CN1369009A (zh) 2002-09-11
HU229156B1 (en) 2013-09-30
DE60019415D1 (de) 2005-05-19
NO332559B1 (no) 2012-10-29
CN103349781A (zh) 2013-10-16
PL208247B1 (pl) 2011-04-29
ZA200110068B (en) 2002-12-06
IL190234A0 (en) 2008-11-03
FR13C0028I1 (fr) 2013-06-14
JP2011024595A (ja) 2011-02-10
NO2013010I2 (no) 2013-05-15
NO2013010I1 (no) 2013-06-17
NZ515913A (en) 2004-01-30
LTC1183353I2 (lt) 2023-02-27
HUS1300052I1 (hu) 2016-08-29
NO20016036D0 (no) 2001-12-10
ES2237429T3 (es) 2005-08-01
CN100523187C (zh) 2009-08-05
CZ302689B6 (cs) 2011-09-07
CA2376379C (en) 2007-08-07
HRP20010908A2 (en) 2005-04-30
IL146890A0 (en) 2002-08-14
PL352246A1 (en) 2003-08-11
CZ20014387A3 (cs) 2002-10-16
SK287332B6 (sk) 2010-07-07
NO20016036L (no) 2002-02-08
HK1185798A1 (en) 2014-02-28
LTPA2013009I1 (lt) 2013-06-25
DE60041159D1 (de) 2009-01-29
CN101433715B (zh) 2013-04-17
JP5273746B2 (ja) 2013-08-28
HK1043388A1 (en) 2002-09-13
PT1544299E (pt) 2009-03-18
AU2005201365B2 (en) 2007-08-09
DK1183353T3 (da) 2005-08-08
MXPA01012630A (es) 2002-07-22
MEP3208A (xx) 2010-02-10
HUP0201515A2 (en) 2002-08-28
UA74146C2 (uk) 2005-11-15
ATE293164T1 (de) 2005-04-15
DK1544299T3 (da) 2009-03-23
KR20020019070A (ko) 2002-03-09
FR13C0028I2 (fr) 2014-05-16
RU2265661C2 (ru) 2005-12-10
KR100659477B1 (ko) 2006-12-20
CY1108883T1 (el) 2014-07-02
JP2003501089A (ja) 2003-01-14
EP1183353B1 (en) 2005-04-13
HRP20010908B1 (en) 2006-05-31
HK1132653A1 (en) 2010-03-05
NO2022060I1 (no) 2022-12-21
NO20100656L (no) 2002-02-08
CY2013019I2 (el) 2015-11-04
EP1183353A1 (en) 2002-03-06
ATE417928T1 (de) 2009-01-15
HUP0201515A3 (en) 2004-12-28
AU779303B2 (en) 2005-01-13
CN103349781B (zh) 2015-04-01
BR0011407A (pt) 2002-04-02
SK17522001A3 (sk) 2003-04-01
PT1183353E (pt) 2005-06-30
EP1544299B1 (en) 2008-12-17
AU2005201365A1 (en) 2005-04-28
ME00024B (me) 2010-02-10
IL146890A (en) 2008-07-08
EP1544299A1 (en) 2005-06-22
LU92195I2 (fr) 2013-07-15
CZ303656B6 (cs) 2013-01-30
NO330775B1 (no) 2011-07-11
WO2000075319A1 (en) 2000-12-14
BRPI0011407B1 (pt) 2018-09-25
DE60019415T2 (de) 2006-03-09
RS50073B (sr) 2009-01-22
JP4723140B2 (ja) 2011-07-13
CY2013019I1 (el) 2015-11-04
HU230159B1 (hu) 2015-09-28
CN101433715A (zh) 2009-05-20
AU5040400A (en) 2000-12-28
BE2013C029I2 (enExample) 2019-03-06

Similar Documents

Publication Publication Date Title
BR0011407A (pt) Molécula de ácido nucléico isolada, polipeptìdeo de fusão, composição, vetor, sistema de vetor, sistema de vetor hospedeiro, métodos de produzir um polipeptìdeo de fusão.
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
BR0009392A (pt) Polipeptìdeo, sequência de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir uma sequência de ácido nucleico mutante e para produzir um polipeptìdeo, mutante de um polipeptìdeo com atividade de alafa-amilase, e, uso do polipeptìdeo ou variante
ATE286907T1 (de) Cytokinin-designiertes lerk-5
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
BR0113921A (pt) ácidos nucléicos e polipeptìdeos receptores
AU9174398A (en) Peptides
BR0009393A (pt) Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para a produção do polipeptìdeo, uso de um polipeptìdeo, e, composição detergente
BR0214350A (pt) Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso
BR9911549A (pt) Processo de produção de fitase em levedura
BR9612359A (pt) Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos
DE69836092D1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
ATE368682T1 (de) Als 2f1 bezeichnetes rezeptorprotein
ATE312186T1 (de) Vektoren und verfahren für rekombinante proteinexpression
AU6542598A (en) Site protected protein modification
BRPI0411112A (pt) proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga
DE69632827D1 (de) Materialen und methoden im zusammenhang mit bindung und präsentation von substanzen auf zelloberflächen
DE69930630D1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
WO2002062999A8 (en) Proteins and nucleic acids encoding same
DE69511399D1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
DE69834565D1 (de) Schnell erzeugung von stabilen säugertier-zellinien mit gewinnung eines hohen gehalts von recombinanten proteine
WO2000069884A3 (en) Compositions isolated from skin cells and methods for their use
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas

Legal Events

Date Code Title Description
B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.007729/2023-82 NUP: 00424.114254/2023-28 (REF. 1029948-81.2023.4.01.3400) POLO ATIVO: REGENERON PHARMACEUTICALS, INC POLO PASSIVO:INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI SENTENCA: DEVERA O INPI PUBLICAR A INFORMACAO DE QUE O PRAZO DE VIGENCIA DA PATENTE OBJETO DESTA ACAO ESTA SUB JUDICE, TANTO NA REVISTA DE PROPRIEDADE INDUSTRIAL, QUANTO NO STATUS DA RESPECTIVA PATENTE NO SITIO DO INPI NA INTERNET (ART. 59, INCISO II, 60 E 226 DA LPI).

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.007729/2023-82 ORIGEM: 7A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1029948-81.2023.4.01.3400 ACAO PELO PROCEDIMENTO COMUM AUTOR: REGENERON PHARMACEUTICALS, INC. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL